Neoadjuvant Therapy for Esophageal Cancer

Area of Science:

• Oncology
• Gastroenterology
• Clinical Trials

Background:

• Esophageal cancer is a highly aggressive malignancy with historically poor outcomes.
• Treatment paradigms have shifted dramatically over the last 20 years.
• Randomized controlled trials have been pivotal in advancing clinical practice.

Purpose of the Study:

• To review the evolution of esophageal cancer management.
• To synthesize evidence from landmark trials.
• To discuss emerging therapies like immunotherapy.

Main Methods:

• Narrative review of evidence-based management strategies.
• Analysis of historical cytotoxic regimens and modern treatment pathways.
• Examination of data on neoadjuvant chemoradiation, chemotherapy, and immunotherapy (checkpoint inhibitors).

Main Results:

• Neoadjuvant chemoradiation and chemotherapy are established treatment modalities.
• Immunotherapy, particularly checkpoint inhibitors, shows emerging promise.
• Challenges remain in treatment selection, response prediction, and toxicity management.

Conclusions:

• Key evidence gaps in esophageal cancer treatment persist.
• Future research should focus on molecular profiling and personalized medicine.
• Ongoing clinical investigations aim to address current therapeutic challenges.